MX352320B - Metodos para la preparacion del compuesto profarmaco de piperazina inhibidor de la union de virus de inmunodeficiencia humana. - Google Patents

Metodos para la preparacion del compuesto profarmaco de piperazina inhibidor de la union de virus de inmunodeficiencia humana.

Info

Publication number
MX352320B
MX352320B MX2014009279A MX2014009279A MX352320B MX 352320 B MX352320 B MX 352320B MX 2014009279 A MX2014009279 A MX 2014009279A MX 2014009279 A MX2014009279 A MX 2014009279A MX 352320 B MX352320 B MX 352320B
Authority
MX
Mexico
Prior art keywords
preparation
methods
prodrug compound
hiv attachment
attachment inhibitor
Prior art date
Application number
MX2014009279A
Other languages
English (en)
Other versions
MX2014009279A (es
Inventor
D Eastgate Martin
S Bultman Michael
Chen Ke
Dustan Fanfair Dayne
J Fox Richard
E La Cruz Thomas
M Mudryk Boguslaw
Ann Risatti Christina
H Simpson James
C Soumeillant Maxime
Clive Tripp Jonathan
Xiao Yi
Original Assignee
Viiv Healthcare Uk No 4 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 4 Ltd filed Critical Viiv Healthcare Uk No 4 Ltd
Publication of MX2014009279A publication Critical patent/MX2014009279A/es
Publication of MX352320B publication Critical patent/MX352320B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/02—Lithium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/098—Esters of polyphosphoric acids or anhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Un método para elaborar el compuesto (AAA) se establece utilizando el material de partida (BBB).
MX2014009279A 2012-02-08 2013-02-06 Metodos para la preparacion del compuesto profarmaco de piperazina inhibidor de la union de virus de inmunodeficiencia humana. MX352320B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261596362P 2012-02-08 2012-02-08
PCT/US2013/024880 WO2013119625A1 (en) 2012-02-08 2013-02-06 Methods for the preparation of hiv attachment inhibitor piperazine prodrug compound

Publications (2)

Publication Number Publication Date
MX2014009279A MX2014009279A (es) 2014-08-27
MX352320B true MX352320B (es) 2017-11-21

Family

ID=47739512

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009279A MX352320B (es) 2012-02-08 2013-02-06 Metodos para la preparacion del compuesto profarmaco de piperazina inhibidor de la union de virus de inmunodeficiencia humana.

Country Status (11)

Country Link
US (9) US8889869B2 (es)
EP (1) EP2812332B1 (es)
JP (1) JP6114314B2 (es)
CN (1) CN104080785B (es)
BR (1) BR112014019289A8 (es)
CA (1) CA2864087A1 (es)
EA (1) EA024872B1 (es)
ES (1) ES2644747T3 (es)
MX (1) MX352320B (es)
PT (1) PT2812332T (es)
WO (1) WO2013119625A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
BR112014019289A8 (pt) 2012-02-08 2017-07-11 Bristol Myers Squibb Co Métodos para a preparação do composto de prome-dicamento de piperazina inibidor da ligação do hiv
KR20170097145A (ko) 2014-12-18 2017-08-25 비브 헬스케어 유케이 (넘버4) 리미티드 Ｐｙｂｒｏｐ를 사용하여 할로겐화된 아자인돌 화합물을 제조하는 방법
RU2017123259A (ru) * 2014-12-18 2019-01-21 ВАЙВ ХЕЛТКЕР ЮКей (N4) ЛИМИТЕД Способ получения галогенированных азаиндольных соединений с использованием бороксина
CN111033808B (zh) * 2017-12-19 2023-04-14 松下知识产权经营株式会社 电池层叠体
EP3911651B1 (en) 2019-01-17 2024-01-10 ViiV Healthcare UK (No.4) Limited Process for preparing fostemsavir

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
CN100384423C (zh) * 2001-02-02 2008-04-30 布里斯托尔-迈尔斯斯奎布公司 取代的氮杂吲哚氧代乙酰哌嗪衍生物的组合物和抗病毒活性
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20040063744A1 (en) * 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
ES2462403T3 (es) * 2008-06-25 2014-05-22 Bristol-Myers Squibb Company Diceto azolopiperidinas y azolopiperazinas como agentes anti-VIH
EP2313408B1 (en) * 2008-06-25 2012-07-11 Bristol-Myers Squibb Company Diketopiperidine derivatives as hiv attachment inhibitors
CA2826260C (en) 2011-01-31 2018-09-04 Bristol-Myers Squibb Company Methods of making hiv attachment inhibitor prodrug compound and intermediates
BR112014019289A8 (pt) 2012-02-08 2017-07-11 Bristol Myers Squibb Co Métodos para a preparação do composto de prome-dicamento de piperazina inibidor da ligação do hiv

Also Published As

Publication number Publication date
PT2812332T (pt) 2017-11-15
US9255113B2 (en) 2016-02-09
US20150038709A1 (en) 2015-02-05
ES2644747T3 (es) 2017-11-30
CN104080785B (zh) 2016-08-31
EA201491446A1 (ru) 2014-11-28
BR112014019289A2 (es) 2017-06-20
US9376458B2 (en) 2016-06-28
EA024872B1 (ru) 2016-10-31
CN104080785A (zh) 2014-10-01
US20150038716A1 (en) 2015-02-05
US9243010B2 (en) 2016-01-26
US20150038712A1 (en) 2015-02-05
US20160152644A1 (en) 2016-06-02
MX2014009279A (es) 2014-08-27
US20160108029A1 (en) 2016-04-21
JP2015508071A (ja) 2015-03-16
EP2812332A1 (en) 2014-12-17
US9394322B2 (en) 2016-07-19
US20130203992A1 (en) 2013-08-08
US20150038717A1 (en) 2015-02-05
US20150038710A1 (en) 2015-02-05
EP2812332B1 (en) 2017-08-09
US8889869B2 (en) 2014-11-18
JP6114314B2 (ja) 2017-04-12
CA2864087A1 (en) 2013-08-15
BR112014019289A8 (pt) 2017-07-11
US9249168B2 (en) 2016-02-02
US9403821B2 (en) 2016-08-02
US20150038711A1 (en) 2015-02-05
WO2013119625A1 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
MD20180040A2 (ro) Inhibitori ai virusului hepatic C
PH12015500263A1 (en) New bicyclic derivatives
UA113643C2 (xx) N-цикліламіди як нематоциди
EP3047030A4 (en) A high yield route for the production of compounds from renewable sources
IN2015DN00598A (es)
MX370649B (es) Proceso para la preparacion de teneligliptina.
MX352320B (es) Metodos para la preparacion del compuesto profarmaco de piperazina inhibidor de la union de virus de inmunodeficiencia humana.
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
JO3318B1 (ar) مثبطات bace
IN2013MU00646A (es)
CR20140495A (es) 5-amino[1,4]thiazines como inhibidores de bace1
EP3027593A4 (en) Piperazine derivatives as hiv protease inhibitors
IN2014DN06964A (es)
IN2014DN07996A (es)
IN2014DN06192A (es)
IN2013MU03070A (es)
MX2015013589A (es) Proceso e intermediario para la preparacion de pregabalina.
MX2016007186A (es) Nuevo procedimiento de sintesis de la agomelatina.
IN2014MU01192A (es)
IN2014MU00195A (es)
IN2014DN09451A (es)
WO2014170909A3 (en) Process for pomalidomide
IN2014MU00194A (es)
IN2014MU01196A (es)
EA201490536A1 (ru) Новая кристаллическая форма

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: VIIV HEALTHCARE UK (NO. 4) LIMITED

FG Grant or registration